NCT06905847View on ClinicalTrials.gov

Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Primary Efficacy of HSK39004 Suspension for Inhalation

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 2, 2024

Primary Completion Date

January 13, 2025

Study Completion Date

March 20, 2025

Conditions

Healthy Donors

Interventions

DRUG

HSK39004 in healthy

1.5-12mg

DRUG

HSK39004

Placebo

DRUG

HSK39004 in COPD

1.5-6mg

Trial Locations (1)

610044

West China Hospital of Sichuan University, Chengdu

All Listed Sponsors

lead

Haisco Pharmaceutical Group Co., Ltd.

INDUSTRY

NCT06905847 - Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Primary Efficacy of HSK39004 Suspension for Inhalation | Biotech Hunter | Biotech Hunter